Volume : 09, Issue : 07, July – 2022
Title:
61.ARE DMARDS BENEFICIAL IN MANAGEMENT OF PSORIASIS?
Authors :
Rania Sami Iraqi
Abstract :
Introduction:Psoriasis is a chronic inflammatory papulosquamous skin disease with genetic predisposition and autoimmune pathogenicity. Psoriasis may also affect the joints as psoriatic arthritis and may even be associated with other conditions. Research into the pathogenesis of Psoriasis in the last few decades has given rise to several targeted therapies. Among them are Disease-modifying anti-rheumatic drugs (DMARDs), mainly used in cases of psoriatic arthritis. The article will review the various disease-modifying anti-rheumatic drugs along with strengths and weaknesses in combating Psoriasis.
The aim of work: An overview is aimed at describing various DMARDs and their use against Psoriasis.
Methodology: The review is a thorough review of PUBMED articles from the year 1984 to 2019 relating to DMARDs and Psoriasis.
Conclusion:Psoriasis is a chronic inflammatory skin disease that also affects other systems of the body due to inflammation. DMARDs are a group of drugs that are used to combat Psoriasis and various other inflammatory ailments. This review briefly discusses the most common examples of DMARDs, their mechanism of action, efficacy in trials, and adverse effects.
Cite This Article:
Please cite this article in press Rania Sami Iraqi et al, Are Dmards Beneficial In Management Of Psoriasis?., Indo Am. J. P. Sci, 2022; 09(7).,
Number of Downloads : 10
References:
1. Parisi R, Symmons D P, Griffiths C E, & Ashcroft D M (2013). Global epidemiology of Psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377-385.
2. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, & Gelfand J M (2013). Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology, 52(3), 568-575.
3. Benjamin O, Bansal P, Goyal A, & Lappin S L (2018). Disease modifying anti-rheumatic drugs (DMARD).
4. Willkens R F, Williams H J, Ward J R, Egger M J, Reading J C, Clements P J, & Weinstein A (1984). Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis & Rheumatism, 27(4), 376-381.
5. Abu-Shakra M A H M O U D, Gladman D D, Thorne J C, Long J, Gough J, & Farewell V (1995). Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. The Journal of Rheumatology, 22(2), 241-245.
6. Gupta A K, Grober J S, Hamilton T A, Ellis C N, Siegel M T, Voorhees J J, & McCune W J (1995). Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. The Journal of rheumatology, 22(5), 894-898.
7. Clegg D O, Reda D J, Mejias E, Cannon G W, Weisman M H, Taylor T, & Henderson W G (1996). Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis & Rheumatism, 39(12), 2013-2020.
8. Kaltwasser J P (2007). Leflunomide in psoriatic arthritis. Autoimmunity reviews, 6(8), 511-514.
9. Curtis J R, Beukelman T, Onofrei A, Cassell S, Greenberg J D, Kavanaugh A, & Kremer J M (2010). Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Annals of the rheumatic diseases, 69(01), 43-47.
10. Steinsson K, Jonsdottir I, & Valdimarsson H (1990). Cyclosporin A in psoriatic arthritis: an open study. Annals of the rheumatic diseases, 49(8), 603-606.
11. Mantravadi S, Ogdie A, & Kraft W K (2017). Tumor necrosis factor inhibitors in psoriatic arthritis. Expert review of clinical pharmacology, 10(8), 899-910.
12. Jeon, C., Sekhon, S., Yan, D., Afifi, L., Nakamura, M., & Bhutani, T. (2017). Monoclonal antibodies inhibiting IL-12,-23, and-17 for the treatment of Psoriasis. Human vaccines & immunotherapeutics, 13(10), 2247-2259.
13. Tian F, Chen Z, & Xu T (2019). Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: a systematic review and meta-analysis. Journal of International Medical Research, 47(6), 2342-2350.
14. Ly K, Smith M P, Thibodeaux Q, Reddy V, Liao W, & Bhutani T (2019). Anti IL-17 in Psoriasis. Expert review of clinical immunology, 15(11), 1185-1194.